Clinical Research

From Early Phases to International Phase III Trials

Our clinical research platforms allow us to conduct phase I to phase III registration trials.

A major advantage of CALYM is the anchor of its research teams in clinical networks formed by the LYSA and the operational structure: LYSARC.

LYSARC brings its operational means and LYSA its scientific experts to several key platforms for the study of lymphoma therapies and biomarkers:

EARLY, Early Phase Clinical and Translational Research Platform

Phases I/IIa, first-in-man, first-in-lymphoma or first combo studies

- Large experience in lymphoma early clinical development: more than 40 trials so far

- Structured and reactive clinical trial management

- Expanded access to patients through a network of selected expert LYSA sites, accredited early-phase centers (“CLIP2″ centers) by the French NCI

- Pharmacokinetics and pharmacodynamics tailored to study treatment

More information on EARLY

LYSA-P, Pathology Platform

Centralized review of patient tumor samples

- More than 16,000 cases reviewed to date

- Dedicated laboratory

- High-tech equipment for digitalization, analysis and sharing of microscopic slides

- Automated high throughput analysis on large patient cohorts

- Large collection of annotated tumors: slides, paraffin blocks, frozen tissue, TMAs, DNA/RNA

LYSA-IM, the Imaging Platform

Central review of patient images

- Up to 4,000 images reviewed per year (PET, TDM, MRI)

- Web exchange platform (Imagys® software) with a FDA approved viewer

- Real-time review (48 hours max) of images used for treatment decision-making

- Research on new evaluation parameters

LYSA-BIO, Biology Platform

Pre-analytical management of biological samples

- Collection, labeling, samples’ management (plasma, DNA/RNA, fresh blood, live cells) in a controlled environment.

- Personalized blood analyses

- Tailored immunological monitoring

- Specific genetic analyses

 

Contact us:+33 (0)4 72 24 41 71, by e-mail
or by submitting your question in the contact form